Diseases & Disorders
(G30)
IRS Verified
DX Registered
990 on File
INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH
Financial strength (30%)
32/100
Reliability (20%)
55/100
Effectiveness (25%)
63/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Mission Statement
IMBCR is the only independent non-profit cancer research institute dedicated to finding improved treatment and ultimately a cure for myeloma and bone cancer. Multiple myeloma is a cancer of malignant blood cells found in the bone marrow and we also conduct research into cancers that find their way into bones that also include breast, lung, and prostate.
Financial Overview — FY 2024
$2.1M
Total Revenue
$1.4M
Total Expenses
$-1,562,143
Net Assets
5
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
23.2%
Fundraising Efficiency
96.2%
Operating Reserve
-13.25x
Liability-to-Asset
204.5%
Revenue Diversification
72.4%
Compared with Peers
FY 2024
Compared with 638 similar organizations
(United States, Diseases & Disorders, $1M–$10M in expenses), FY 2024.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
23.2% | 82.3% |
P10P90
|
Bottom quarter |
|
Admin expense ratio
Management and general / total expenses
· lower is better
|
71.1% | 11.5% |
P10P90
|
Bottom quarter |
|
Fundraising expense ratio
Fundraising expenses / total expenses
· lower is better
|
5.7% | 2.8% |
P10P90
|
Below median |
|
Fundraising efficiency
Fundraising expenses / gross fundraising income
· lower is better
|
96.2% | 110.9% |
P10P90
|
Above median |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
-13.3 mo | 11.4 mo |
P10P90
|
Bottom quarter |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
204.5% | 12.7% |
P10P90
|
Bottom quarter |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
72.4% | 91.5% |
P10P90
|
Top quarter |
|
Revenue growth
Year over year revenue growth
|
86.5% | 9.6% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
9.4% | 8.8% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
33.8% | 2.2% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2024 | $2.1M | $1.4M | $-1,562,143 | 23.2% | 5 |
| 2023 | $1.1M | $1.3M | $-2,284,772 | 23.8% | 5 |
| 2022 | $2.3M | $1.5M | $-2,137,687 | 18.6% | 7 |
| 2021 | $1.4M | $2.7M | N/A | — | 7 |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.